YORBA LINDA, Calif. (PRWEB) November 14, 2017
(HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins function as GDP-GTP regulated binary on-off switches that regulate diverse cytoplasmic signaling networks. In cancer and developmental disorders (RASopathies), mutationally activated RAS proteins drive aberrant signal transduction.
RAS proteins are also the founding members of a large superfamily of small GTPases comprised of less than 150 members. Since their initial identification decades ago as drivers of human cancers, there has been intense interest and effort in targeting RAS for cancer treatment. RAS genes are the most frequently mutated oncogenes in the top three causes of cancer deaths in the US in 2016, including lung, colorectal and pancreatic cancers.
In this webinar, participant will learn of the vulnerabilities of RAS that have been exploited for the development of pharmacologic inhibitors of RAS function. They will understand the RAS function in cytoplasmic signaling and the potential therapeutic role of anti-RAS therapy in Cancer.
The team at Bio-Techne has arranged to sponsor this exciting webinar featuring Dr. Adrienne Cox, an associate professor of radiation oncology and pharmacy at the University of North Carolina at Chapel Hill.
Cox is the Chief of the Division of Cancer Research in the Department of Radiation Oncology at the University of North Carolina at Chapel Hill (UNC-CH), where she directs UNC-CH's NCI-funded Cancer Cell Biology T32 Training Program. She received her BA from Pomona College, her doctorate from Eastern Virginia Medical School, and performed her postdoctoral studies at the La Jolla Cancer Research Foundation. Cox's research encompasses basic science aspects of RAS family signaling and transformation as well as translational aspects such as the development of farnesyltransferase inhibitors, originally intended to be anti-RAS therapeutics.
LabRoots will host the webinar November 29, 2017, beginning at 10 a.m. PST, 1 p.m. EST. To learn more about this event, find out about the continuing education credits offered, or to register for free, click here.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in-situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota. The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.